Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding

AIDS

Volumn 31, Issue 2, 2017, Pages 213-232

  Mofenson, Lynne M ^a   Baggaley, Rachel C ^b   Mameletzis, Ioannis ^b  

^a ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Breastfeeding; Drug safety in pregnancy and breastfeeding; Preexposure prophylaxis; Pregnancy; Tenofovir disoproxil fumarate

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR;

ABNORMAL VALUE; ADVERSE OUTCOME; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY; ARTICLE; BONE DENSITY; BONE MINERAL; BREAST FEEDING; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LOW BIRTH WEIGHT; MATERNAL MORTALITY; NEWBORN MORTALITY; OBSERVATIONAL STUDY; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; SMALL FOR DATE INFANT; STILLBIRTH; ADVERSE DRUG REACTION; AFRICA SOUTH OF THE SAHARA; DISEASE TRANSMISSION; INFANT; NEWBORN; PRE-EXPOSURE PROPHYLAXIS; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; BREAST FEEDING; DISEASE TRANSMISSION, INFECTIOUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; TENOFOVIR;

EID: 84994726334     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001313     Document Type: Article

References (50)

1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 2016; 30:1973- 1983.
2. Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, et al. Preventing HIV-1 infection in women using oral preexposure prophylaxis: A meta-Analysis of current evidence. J Acquir Immune Defic Syndr 2016; 73:606-608.
3. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection - recommendations for a public health approach - second edition, 2016. Geneva, Switzerland: World Health Organization, 2016. http://www.who.int/hiv/pub/arv/arv-2016/en/[Accessed 16 August 2016].
4. Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-Tochild HIV transmission: A systematic review and meta-Analysis. PLoS Med 2014; 11:e1001608.
5. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. [Accessed 21 March 2016].
6. Viganò A, Mora S, Giacomet V, Stucchi S, Manfredini V, Gabiano C, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIVuninfected children born to HIV-infected mothers. Antivir Ther 2011; 16:1259-1266.
7. Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, et al., DART trial team. Pregnancy and infant outcomes among HIV-infected women taking long-Term ART with and without tenofovir in the DART trial. PLoS Med 2012; 9:e1001217.
8. Siberry GK, Williams PL, Mendez H, Seage GR 3rd, Jacobson DL, Hazra R, et al., Pediatric HIV/AIDS Cohort Study (PHACS). Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26:1151-1159.
9. Maskew M, Westreich D, Firnhaber C, Sanne I. Tenofovir use and pregnancy among women initiating HAART. AIDS 2012; 26:2393-2397.
10. Floridia M, Mastroiacovo P, Tamburrini E, Tibaldi C, Todros T, Crepaldi A, et al., Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. BJOG 2013; 120:1466-1475.
11. Ransom CE, Huo Y, Patel K, Scott GB, Watts HD, Williams P, et al., P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr 2013; 64:374-381.
12. Phiri K, Hernandez-Diaz S, Dugan K, Williams PL, Dudley JA, Jules A, et al. First trimester exposure to antiretroviral therapy and risk of birth defects. Pediatr Infect Dis J 2014; 33:741- 746.
13. Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag- Bonnet N, Faye A, et al. Association between prenatal exposure to antiretroviral therapy and birth defects: An analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med 2014; 11:e1001635.
14. Onyango-Makumbi C, Matovu JN, Mubiru M, et al. Effect of antiretroviral regimens on bone mineral density of HIV-infected lactating Ugandan women. Conference on Retroviruses and Opportunistic Infections. February 2014, Boston, MA. Abs. 850.
15. Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K, et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr 2015; 169:48-55.
16. Himes SK, Wu JW, Jacobson DL, Tassiopoulos K, Hazra R, Kacanek D, et al., Pediatric HIVAIDS Cohort Study (PHACS). Meconium tenofovir concentrations and growth and bone outcomes in prenatally tenofovir exposed HIV-uninfected children. Pediatr Infect Dis J 2015; 34:851-857.
17. Siberry GK, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, et al., Pediatric HIV/AIDS Cohort Study. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis 2015; 61:996-1003.
18. Pintye J, Langat A, Singa B, Kinuthia J, Odeny B, Katana A, et al. Maternal tenofovir disoproxil fumarate use in pregnancy and growth outcomes among HIV-exposed uninfected infants in Kenya. Infect Dis Obstet Gynecol 2015; 2015:276851.
19. Fowler MG, Qin M, Fiscus S, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med 2016; 375:1726-1737.
20. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry Interim Report for 1 Jan 1989 through 31 January 2016. Wilmington NC: Registry Coordinating Center, 2016.
21. Moodley T, Moodley D, Sebitloane M, Maharaj N, Sartorius B. Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. BMC Pregnancy Childbirth 2016; 16:35.
22. Zash R, Souda S, Chen JY, Binda K, Dryden-Peterson S, Lockman S, et al. Reassuring birth outcomes with tenofovir/emtricitabine/efavirenz used for prevention of mother to child transmission of HIV in Botswana. J Acquir Immune Defic Syndr 2016; 71:428-436.
23. Malaba T, Phillips T, Le Roux S et al. Timing of ART initiation in pregnancy and birth outcomes in South African women. Conference on Retroviruses and Opportunistic Infections. February 2016, Boston, MA. Abs. 799.
24. Le Roux SM, Jao J, Brittan K, et al. Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants: A prospective study. AIDS 2017; 31:97-104.
25. Siberry GK, Tierney C, Stranix-Chibanda L, et al. P1084s: impact of maternal tenofovir disoproxil fumarate (TDF) use on HIV-exposed newborn bone mineral content. Conference on Retroviruses and Opportunistic Infections. February 2016, Boston, MA. Abs. 36.
26. Jao J, Abrams EJ, Phillips T, Petro G, Zerbe A, Myer L. In utero tenofovir exposure is not associated with fetal long bone growth. Clin Infect Dis 2016; 62:1604-1609.
27. Denneman L, Cohen S, Godfried MH, van Leeuwen E, Nellen JF, Kuijpers TW, et al. In utero exposure to tenofovir is associated with impaired fetal and infant growth: need for followup studies in combination antiretroviral therapy/HIV-exposed infants. AIDS 2016; 30:2135-2143.
28. Liotta G, Floridia M, Andreotti M, Jere H, Sagno JB, Marazzi MC, et al. Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants. AIDS 2016; 30:525-527.
29. Floridia M, Liotta G, Andreotti M, Galluzzo CM, Amici R, Jere H, et al. Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option BR programme in Malawi. J Antimicrob Chemother 2016 July 11 [Epub ahead of print].
30. Taha T, Flynn P, Cababasay M, et al. Comparing maternal triple antiretrovirals (mART) and infant nevirapine (iNVP) prophylaxis for the prevention of mother to child transmission (MTCT) of HIV during breastfeeding (BF). AIDS Conference, July 18-22 2016, Durban, South Africa. Abs. LBPE013.
31. Stranix-Chibanda L, et al. for PROMISE 1084s Study Team. Impact of tenofovir-containing triple antiretroviral therapy (ART) on bone mineral density in HIV-infected breastfeeding women in sub-Saharan Africa. 8th International Workshop on HIV Pediatrics. Durban, South Africa, July 15-16, 2016 (Abstract 020).
32. Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013; 28:9377-9382.
33. Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014; 61:502-507.
34. Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al., Taiwan Study Group for the Prevention of Mother-To-Infant Transmission of HBV (PreMIT Study); Taiwan Study Group for the Prevention of Mother-To-Infant Transmission of HBV PreMIT Study. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-To-infant transmission of hepatitis B virus. Hepatology 2015; 62:375-386.
35. Kochaksaraei SG, Castillo E, Osman M, Simmonds K, Scott AN, Oshiomogho JI, et al. Clinical course of 161 untreated and tenofovir-Treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepat 2016; 23:15-22.
36. Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al., China Study Group for the Mother-To-Child Transmission of Hepatitis B. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 2016; 374:2324-2334.
37. Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John- Stewart G, et al., Partners PrEP Study Team. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: A randomized clinical trial. JAMA 2014; 312:362-371.
38. Bunge K, Balkus J, Noguchi L, et al. Pregnancy incidence and outcomes in women receiving tenofovir-based PrEP in the VOICE trial. International AIDS Conference. July 2015, Vancouver, Canada. Abs. MOPEC480.
39. Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, et al. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother 2009; 53:2367-2374.
40. Colbers APH, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, et al., PANNA Network. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS 2013; 27:739-748.
41. Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, et al., HPTN 057 Protocol Team. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr 2014; 65:33-41.
42. Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, et al., International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) P1026s Team. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med 2015; 16:502-511.
43. Benaboud S, Pruvost A, Coffie PA, Ekouévi DK, Urien S, Arrivé E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011; 55:1315-1317.
44. Palombi L, Pirillo MF, Marchei E, Jere H, Sagno JB, Luhanga R, et al. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. J Antimicrob Chemother 2016; 71:1027- 1030.
45. Mugwanya K, Hendrix CW, Mugo NR, Marzinke M, Katabira ET, Ngure K, et al. Preexposure prophylaxis use by breastfeeding HIV-uninfected women: A short-Term study of antiretroviral excretion in breastmilk and infant absorption. PLoS Med 2016; 13:e1002132.
46. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206:1695-1705.
47. Matthews LT, Heffron R, Mugo NR, Cohen CR, Hendrix CW, Celum C, et al. High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis. J Acquir Immune Defic Syndr 2014; 67:91-97.
48. Mirembe BG, Kelly CW, Mgodi N, Greenspan S, Dai JY, Mayo A, et al., MTN-003B Protocol Team. Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis. J Acquir Immune Defic Syndr 2016; 71:287-294.
49. Price JT, Wheeler SB, Stranix-Chibanda L, Hosek SG, Watts DH, Siberry GK, et al. Cost-effectiveness of preexposure prophylaxis during pregnancy and breastfeeding in sub-Saharan Africa. J Acquir Immune Defic Syndr 2016; 72 (Suppl 2):S145- S153.
50. Mofenson LM. Tenofovir preexposure prophylaxis for pregnant and breastfeeding women at risk of HIV infection: The time is now. Plos Med 2016; 13:e1002133.